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Abstract
Background: Varicella is a highly infectious disease with a significant public health and economic burden, which
can be prevented with childhood routine varicella vaccination. Vaccination strategies differ by country. Some factors
are known to play an important role (number of doses, coverage, dosing interval, efficacy and catch-up
programmes), however, their relative impact on the reduction of varicella in the population remains unclear. This
paper aims to help policy makers prioritise the critical factors to achieve the most successful vaccination
programme with the available budget.
Methods: Scenarios assessed the impact of different vaccination strategies on reduction of varicella disease in the
population. A dynamic transmission model was used and adapted to fit Italian demographics and population
mixing patterns. Inputs included coverage, number of doses, dosing intervals, first-dose efficacy and availability of
catch-up programmes, based on strategies currently used or likely to be used in different countries. The time
horizon was 30 years.
Results: Both one- and two-dose routine varicella vaccination strategies prevented a comparable number of
varicella cases with complications, but two-doses provided broader protection due to prevention of a higher
number of milder varicella cases. A catch-up programme in susceptible adolescents aged 10–14 years old reduced
varicella cases by 27–43 % in older children, which are often more severe than in younger children. Coverage, for
all strategies, sustained at high levels achieved the largest reduction in varicella. In general, a 20 % increase in
coverage resulted in a further 27–31 % reduction in varicella cases. When high coverage is reached, the impact of
dosing interval and first-dose vaccine efficacy had a relatively lower impact on disease prevention in the
population. Compared to the long (11 years) dosing interval, the short (5 months) and medium (5 years) interval
schedules reduced varicella cases by a further 5-13 % and 2-5 %, respectively. Similarly, a 10 % increase in
first-dose efficacy (from 65 to 75 % efficacy) prevented 2–5 % more varicella cases, suggesting it is the least
influential factor when considering routine varicella vaccination.
Conclusions: Vaccination strategies can be implemented differently in each country depending on their needs,
infrastructure and healthcare budget. However, ensuring high coverage remains the critical success factor for
significant prevention of varicella when introducing varicella vaccination in the national immunisation programme.
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Background
Varicella is a highly infectious childhood disease caused
by varicella-zoster virus (VZV). Each year, the total
number of varicella cases in all age groups more or less
equals the size of the birth cohort, in countries with no
routine varicella vaccination (RVV) programme [1]. In
addition, seroprevalence studies in Europe have shown
that over 90 % of people have been infected with vari-
cella by 10–15 years of age [2].
Many patients with varicella will visit a general practi-
tioner (GP) and 2–6 % of those cases will have complica-
tions, while the annual incidence of varicella
hospitalisations in Europe is 1.9 to 5.8 per 100,000 popu-
lation [3]. The high infection rates and associated
economic burden of varicella result in a significant
public health burden [4].
Varicella infection can be prevented through effective
varicella vaccines with well-established immunogenicity,
reactogenicity and safety profiles [3]. In countries where
RVV programmes have been implemented, a significant
reduction in the incidence and burden of varicella has
been observed [3]. Therefore, the World Health
Organization (WHO) recommends that a RVV
programme should be considered in countries where
varicella has an important public health burden and
where high (>80 %) coverage can be sustained [5].
With increasing constraints on healthcare budgets,
policy makers need more clarity on which vaccination
strategy to choose for optimal reduction of the disease
burden. Several practical aspects that need consideration
include how to reach and sustain high coverage levels in
order to optimise protection against varicella disease.
Other factors that influence the impact of vaccination in-
clude the choice of using either one-dose or two-dose vac-
cination schedules, either short (months) or long (years)
intervals between two doses, and whether or not a catch-
up programme should be implemented when introducing
childhood RVV. RVV will be introduced in Italy as a na-
tional programme in the near future, following analysis of
the vaccine data from eight pilot regions which have already
implemented it. An Interregional Group on Varicella Vac-
cination (IGVV) was established in 2013 to assess the vari-
cella vaccination effectiveness using common standardised
methods. Since 2003, eight Italian regions (Basilicata,
Calabria, Friuli - Venezia Giulia, Apulia, Sardinia, Sicily,
Tuscany and Veneto) started to introduce childhood RVV
(in children aged 13–15 months and 5–6 years) in their
regional immunisation programmes, using different sched-
ules. Currently all regions use a two-dose schedule [6].
The objective of this model-based study is to help pol-
icy makers choose an appropriate vaccination strategy in
their country, by exploring the relative impact of several
key factors on varicella burden: (1) coverage, (2) one-
dose or two-dose schedule, (3) vaccine efficacy of the
first dose, (4) short or long interval between doses, and
(5) whether or not to implement a catch-up programme.
Although this study aims to inform RVV policy makers
in general, the example of Italy was used, given the
diverse regional strategies currently in place and antici-
pated policy changes.
Methods
An age-structured dynamic transmission model was
developed, based on the framework described by Brisson
et al. [7, 8] and following the same methodology used for
the adaptation for France [9], to assess the impact of vari-
cella vaccination on disease burden by varying the key
influential vaccination strategy parameters. The model
predicts both varicella and zoster diseases over a lifetime
with and without vaccination to reflect the full picture of
the disease burden related to VZV. The model structure
shows varicella disease states as susceptible, latent or
exposed, infectious, and recovered. Factors such as waning
of vaccine efficacy over time and the influence of popula-
tion migration on infection rates were included. The
model was adapted to match the epidemiology of varicella
prior to vaccination in Italy using an empirically-derived
contact matrix [10]. A detailed description of the model
can be found in Additional file 1. The incidence of vari-
cella before vaccination was compared to the predicted
incidence over time following the introduction of vaccin-
ation in the model. Based on these comparisons, the
percentage reduction in varicella cases is presented post-
vaccine introduction for all combinations of dosing, cover-
age and efficacy tested. After introducing childhood RVV,
milder ‘breakthrough’ cases of varicella can occur in the
model. The predicted incidence of varicella over time for
each scenario is presented below.
Model assumptions and scenarios (see Table 1)
The model assumed that the maximum vaccine cover-
age would gradually be attained in the first 3 years of
introducing the RVV programme. Three vaccination
coverage scenarios were considered for dose one & dose
two; including high (i.e., 95 & 80 %), medium (i.e., 85 &
70 %) and low coverage (i.e., 75 & 60 %).
Two different values were assessed for vaccine efficacy
of the first dose (i.e., 65 or 75 %). For two-dose sched-
ules, vaccine efficacy following the second dose was
fixed at 95 % [11].
Three scenarios were considered to assess the impact
of a longer or shorter interval between the two vaccine
doses; including a 5-month, a 5-year and an 11-year
interval. These intervals were based on current Measles,
Mumps and Rubella (MMR) schedules used in different
countries, while in Italy several regions have typically
used a 4-or 5-year interval between doses.
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All dosing scenarios included a catch-up programme
in adolescents (12-year-olds) who were still susceptible
to varicella (i.e., not vaccinated and had not yet had vari-
cella). The catch-up programme, with a coverage of
20 %, was modelled for the first 11 years since introdu-
cing vaccination. From the twelfth year, the original
vaccinated cohort will have reached the age of 12 years,
and would therefore be protected. A scenario presents
the impact of not including a catch-up programme.
Results
Increasing coverage or efficacy, or shortening the dosing
interval had a positive effect on the prevention of
varicella but each to a different extent. The impact of
various vaccination strategies on varicella prevention are
presented below.
Routine varicella vaccination of toddlers and children:
impact of the number of doses
The first practical issue to consider when implementing
RVV is the choice to use a one- or two-dose vaccination
programme. As per our modelling results, a one-dose
schedule effectively controls varicella disease albeit with
the presence of mild breakthrough cases, whilst a two-
dose schedule provides optimal protection against mild
and severe varicella with the potential to reduce break-
through varicella cases in the population. The baseline
varicella incidence before introduction of RVV was
910.4 per 100,000 population per year. Varicella inci-
dence decreased immediately after introduction of the
vaccine, with by year 30 around 70 % reduction (inci-
dence of 273.0/100,000) and around 40 % reduction
(546.0/100,000) across all age groups for two- and one-
dose strategies, respectively (Fig. 1). The overall number
of complications due to varicella was 43 per 100,000
population per year. The reduction in number of com-
plications in the first 15 years of post-introduction of
vaccination was substantial (up to 90.1 % for two-dose
and up to 84.6 % for one-dose strategies). Between 15
and 30 years post - introduction of vaccination, there
was a peak in complications with one-dose strategies (up
to 18.7/100,000 after 19 years), reflecting the peaks in
incidence (Fig. 3), and due to accumulation of non-
vaccinated varicella cases. However, this difference
became minimal (6.0 %) between the two strategies after
30 years of vaccination (Fig. 2)
Routine varicella vaccination of toddlers and children:
impact of the coverage
Whether considering a one-dose or two-dose vaccin-
ation strategy, it is important to understand the impact
of vaccination coverage on varicella disease burden in
the population. Within each vaccination strategy consid-
ered in the model, it is apparent that high coverage was
the key driver of vaccine impact on varicella (Fig. 1).
A low coverage reduced varicella by 64.1, 58.3 and
55.0 % (to 327, 380 and 410/100,000) with a two-dose
strategy and short, medium and long dosing intervals,
respectively. When coverage was high, an additional 27.2–
31.1 % reduction in varicella cases was observed. The dis-
proportionate improvement in outcomes (i.e., vaccinating
20 % more children provides around 30 % fewer varicella
cases in the population) highlights the additional indirect
benefit vaccination provides at higher coverage levels, by
providing herd immunity (Figs. 1 and 3).
The effect of a 10 % increase from low to medium
coverage and from medium to high coverage, respect-
ively, was to reduce varicella cases by an additional
15.0 % (to 190.1/100,000) and 12.2 % (78.8/100,000) with
the short dosing interval, 12.7 % (263.7/100,000) and
17.5 % (104.1/100,000) with the medium dosing interval,
and, 11.1 % (309.1/100,000) and 19.9 % (127.4/100,000)
with the long dosing interval (see Fig. 1).
Routine varicella vaccination of toddlers and children:
impact of the dosing interval
Within two-dose schedules, there is further debate about
whether a short-term (5 months) or longer term (5 or
11 years) interval should be used.
Shortening the dosing interval resulted in an add-
itional 3-8 % reduction in varicella cases (from 5 years
dosing interval to 6 months) and 2-5 % reduction (from
Table 1 Scenario analyses
Parameter Values Source
Vaccination coverage:
1st dose & 2nd dose (VC D1_D2)
95–80 %
85–70 %
75–60 %
Assumptions
Vaccine efficacy (VE):
for 1st dose
65 %
75 %
Prymula et al. [11]
Assumption
Vaccine efficacy (VE) for 2nd dose 95 % (fixed) Prymula et al. [11]
Dosing interval scenarios
Age at 1st dose & 2nd dose
Short (1–1.5 years): 13 months & 1.5 years
Medium (1–6 years): 13 months & 6 years
Long (1–12 years): 13 months & 12 years
Assumptions
Catch-up programme For susceptible 12-year-olds, for 11 years, 20 % coverage Assumptions
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Fig. 1 Percentage reduction in varicella incidence (a) and incidence per 100,000 popn (b) across all age groups at 30 years after vaccination, for
different coverage, efficacy and dosing scenarios compared with no varicella vaccination. Legend: VC (vaccine coverage 1st dose_2nd dose), VE
(1st dose vaccine efficacy)
Fig. 2 Complications among natural (N) and breakthrough (BK) varicella cases with a one-dose and two-dose vaccination strategy. Legend: 1D
(one-dose), 2D (two-dose), N (natural), BK (breakthrough). Note: Complications among breakthrough cases were close to 0 with both one-and
two-dose strategies
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Fig. 3 Varicella incidence (per 100,000 population) following RVV for each scenario. Legend: VE (vaccine efficacy), VC (vaccine coverage 1st dose_2nd
dose), 1D (one-dose)
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11 years dosing interval to 5 years). The overall 5-13 %
reduction in number of varicella cases was observed
when 6 months between the two doses was considered
instead of 11 years (Fig. 1). Changes in dosing interval
appear to have a smaller impact on varicella burden than
changes in coverage.
Routine varicella vaccination of toddlers and children:
impact of the first-dose efficacy
With a one-dose vaccination schedule and 75 % vaccine
efficacy post-dose one, a 37.5 % (to 569/100,000) and
47.4 % (479/100,000) reduction in varicella cases was
observed with low and high coverage, respectively.
With 65 % efficacy post-dose one, the percentage of
varicella cases prevented was 35.0 % (601/100,000) and
45.4 % (497/100,000), which is only slightly lower (2–3 %),
showing that a 10 % drop in efficacy of dose one would not
have a significant impact on overall disease prevention.
Similarly with a two-dose vaccination schedule and
75 % efficacy post-dose one, the reduction in varicella
cases ranged from 55.0 % (low coverage and long inter-
val) to 91.3 % (high coverage and short interval). This
was comparable to the 52.5 % (low coverage and long
interval) to 89.2 % (high coverage and short interval)
reduction observed with 65 % efficacy post-dose one
(Fig. 1).
Routine varicella vaccination of toddlers and children:
impact of a catch-up programme
The impact of a catch-up programme on disease burden
was assessed for both a one-dose and two-dose strategy,
using a coverage of 85 % for the first dose and 70 % for
the second dose. Figure 4 shows that the catch-up
programme substantially reduced the second peak in
incidence of varicella that is predicted to occur around
ten years after introducing childhood RVV, by 47.4 % (to
350.8/100,000) with a two-dose strategy and by 25.5 %
(to 428.4/100,000) with a one-dose strategy. Without
introduction of catch - up programme the incidence of
varicella at around 10 years post - introduction of vac-
cination was 667.6 and 575.2/100,000 for a two-dose and
one-dose strategy, respectively (Fig. 4a and b).
Figure 5 shows the breakdown of varicella cases by age
group predicted to occur at given time points after
introducing childhood RVV, with and without a catch-
up programme, using the example of the two-dose strat-
egy. The impact of the catch-up programme ten years
after introducing childhood RVV was to significantly
reduce the overall incidence of varicella (by 47.4 %, from
667.6 to 350.8/100,000), as well as to reduce the
incidence in the 10–14 year age group (by 79.9 %, from
94.8 to 19.1/100,000) compared with having no catch-up
programme.
Discussion
The WHO position is that countries should consider
introducing varicella vaccination into the routine
immunisation programme where varicella is an import-
ant public health burden. They recommend that these
countries have sufficient resources to maintain high
coverage. Currently, eight countries recommend child-
hood RVV in the European Union, either at the national
or regional level, while sixteen countries recommend
targeted vaccination of susceptible teenagers or at-risk
groups [3]. Several practical factors related to vaccin-
ation strategy need to be taken into consideration as
they play a key role in determining the impact of a RVV
programme on varicella cases in the population; such as
how to optimise coverage, choice of dosing strategy and
whether to implement a catch-up programme.
Following the introduction of childhood RVV, there is
a period when incidence rates fluctuate, this is common
with infectious disease models which typically assume
homogenous contacts and transmission risk within each
age group and include a dynamic relation between the
force of infection, the proportion of infectious and
susceptible individuals. In our case, other factors can
influence these variations such as the highly infectious
nature of varicella, the changes in coverage rates over
time and the temporary implementation of a catch-up
programme.
This study considered many possible vaccination sce-
narios such as one- or two-dose schedule, different
coverage rates, dosing intervals, efficacy post-dose one
and availability of a catch-up programme to predict the
reduction of varicella burden in the population following
a childhood RVV programme. The results of this ana-
lysis have shown that the most influential factor in redu-
cing varicella incidence was high coverage. A shorter
interval between two doses improved outcomes further,
while the impact of a 10 % change in first-dose efficacy
was less significant whether with a one- or two-dose
strategy.
Varicella vaccination programmes have been imple-
mented in different ways, with some countries imple-
menting a childhood RVV programme while other
countries target only high-risk groups. Among countries
with a RVV programme, a one-dose schedule has been
publicly funded in Australia since 2005 [12] with a
coverage of over 80 % resulting in important reductions
in varicella morbidity and mortality [13, 14]. Whereas in
the USA and Germany, the initial one-dose schedule
was replaced by a two-dose schedule after some years,
resulting in even greater disease prevention in the popu-
lation [15, 16]. Breakthrough varicella is thought to be
caused mainly by primary vaccine failure rather than
vaccine efficacy waning [17]. This could explain why
countries implementing a two-dose schedule were able
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to further reduce the incidence of breakthrough cases
compared to those using one-dose schedules [3]. Data
from active surveillance in the USA show that a one-
dose schedule was able to significantly decrease the
number, size and duration of varicella outbreaks, how-
ever the addition of a second dose was able to nearly
eliminate outbreaks [3]. When comparing a one-dose
and two-dose strategy in this study, both were found to
significantly reduce the burden of varicella, however the
impact with a two-dose strategy was greater. Although a
one-dose vaccination strategy prevented fewer varicella
cases, its prevention of severe cases (i.e., with complica-
tions) was comparable to two-dose strategies. Evidence
from countries with childhood RVV supports the finding
that one-dose strategies have higher efficacy against
more severe than less severe varicella, while two-dose
a
b
Fig. 4 Influence of a catch-up programme on varicella incidence with a one-dose and two-dose strategy. Legend: 1D (one-dose), 2D (two-dose),
VC (vaccine coverage 1st dose_2nd dose)
Fig. 5 Influence of a catch-up programme on age-specific incidence of varicella (two-dose scenario). Legend: y (year). Note: The vaccine strategy
in Fig. 5 included dosing at 1y and 6y with coverage of 85 and 75 % respectively
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strategies have high efficacy against any varicella regard-
less of severity [3]. Therefore, the main benefit of a one-
dose schedule appears to be in reducing mortality and
severe morbidity, while a two-dose schedule has been
found to reduce the disease burden irrespective of sever-
ity and to prevent cases of breakthrough infection [18].
Maintaining high vaccine coverage is critical to provid-
ing substantial protection for the population, whether
with a one-dose or two-dose vaccination strategy, given
the highly infectious nature of VZV. The model findings
are consistent with WHO recommendations in that sus-
taining coverage of 85 % or higher with a RVV
programme will have an optimal impact. Our findings
show that a high coverage was also able to compensate
for other vaccination strategies which may be less effect-
ive at reducing varicella burden, such as longer interval
between doses and lower vaccine efficacy post-dose one.
In countries where childhood RVV has been imple-
mented with high coverage rates, surveillance data have
shown significant and rapid reductions in varicella
disease burden (cases, complications, hospitalisations
and deaths) observed in all age groups including non-
vaccinated age groups such as infants and adults,
demonstrating herd protection effects [3].
This study found that shortening the dosing interval
increased the number of cases prevented, although the
effect was less important than increasing coverage rate.
Another benefit of a short interval between doses is that
this could help reduce the risk of breakthrough varicella
in the interval between doses [17]. In Italian regions
where childhood RVV has already been introduced, the
first dose is given around the 13th to 15th month of life
and the second dose around the 5th to 6th year of life;
thus with a 4- to 5-year interval between doses [6].
There is evidence from three recent Italian studies show-
ing that a long-interval schedule does not significantly
affect the performance of a two-dose varicella vaccin-
ation programme [6, 19, 20]. These studies reported very
high rates of disease reduction across eight regions of
Italy (Apulia, Basilicata, Calabria, Friuli-Venezia Giulia,
Sardinia, Sicily, Tuscany and Veneto) that implemented
childhood RVV between 2003 and 2013; overall inci-
dence decreased from 6.7 per 1000 population in 2003
to 1.7 per 1000 population in 2012. In Sicily, which was
the first Italian region to implement varicella vaccin-
ation, there was a 95 % reduction in cases over 10 years,
with coverage rates increasing to 85 % [20]. So while a
shorter interval favours fewer cases of varicella, the lar-
gest driver of prevention is higher coverage. In the USA,
despite a long interval between doses [21], a clear benefit
of vaccination was observed with a high coverage of
90 % for infants targeted for vaccination [22, 23]. This
supports the finding that coverage is a more important
factor than dosing interval in determining the success of
a childhood RVV programme. When deciding on dosing
schedules, countries should therefore consider fitting in
varicella vaccinations with their current immunisation
schedule, by assessing the number of vaccines currently
given at different ages and the timing of visits, to help
improve coverage for their RVV programme. Combining
the second dose of varicella vaccination with a scheduled
visit for other childhood vaccinations could help to
increase coverage of the second dose.
The choice of using MMR with a single antigen vari-
cella vaccine (MMR + V) or the combined MMRV
depends on country-specific preferences, given the
uncertainty surrounding potential increased febrile
convulsion risks with the first dose of MMRV. An asso-
ciation was seen in clinical trials and observational stud-
ies between the administration of the first dose of
MMRV and febrile convulsions, compared with MMR +
V vaccination [24, 25]. German data found one add-
itional case of febrile convulsion with MMRV per 5882
or 2747 vaccinees compared with MMR or MMR +V,
respectively [24, 26]. Other studies also found a small
increased risk of febrile convulsions in the second week
post-vaccination [26–28]. By contrast, the region of
Tuscany in Italy decided to keep MMRV for the first
dose as they had not observed an increased risk of any
adverse events due to MMRV compared with MMR +V
[29]. In another study, the incidence febrile convulsions
in the 40-day post-vaccination period did not differ
between MMR +V and MMRV. There was a minimal
impact of MMRV on the overall population risk of
febrile convulsions, with an excess risk of 3.52 febrile
convulsions per 10,000 vaccinees compared to MMR + V
[27]. There was no change in the baseline incidence of
febrile convulsions in the population as a whole follow-
ing the introduction of MMRV. The small increased risk
of febrile convulsions occurring within the first 2 weeks
of administration of MMRV vaccine must be balanced
against administering separate MMR and varicella vac-
cines [26, 28], potentially impacting vaccine uptake [30].
The eight Italian regions that provided RVV offered two
doses of MMRV, MMR +V or single antigen V, given at
different times and sometimes in combination with ap-
pointments for different vaccines [6]. Coverage is linked
to dosing strategy; in countries where there is a high
MMR coverage, switching to MMRV does not appear to
affect coverage, but switching to MMR + V tends to
result in a lower V coverage. In Germany, the uptake of
varicella vaccination (but not MMR) decreased by 4–
19 % when the national recommendations changed from
the administration of MMRV to MMR +V [30]. Benefit/
risk assessment suggests that the use of MMRV instead
of MMR +V can prevent an additional 1976 varicella-
related hospitalisation days per year at the cost of an
additional 225 vaccine-related febrile convulsions
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hospitalisation days when coverage drops by 12 %. That
is the trade-off between the two vaccination schemes
that needs to be considered when making decisions on
their use in immunisation programmes [31].
The primary goal of a varicella vaccination programme
is to generate a public health impact by reducing the
number of varicella cases and related hospitalisations
and deaths. In 2000, using mathematical models, Brisson
et al. [7] showed a temporal immediate increase in
herpes zoster (HZ) incidence post-vaccination. However,
medium-term epidemiological evidence is now available
from several countries that have implemented varicella
vaccination. The majority of these studies concluded that
HZ incidence was either not increasing, or the increase
was not directly related to varicella vaccination [13, 32,
33], or that the study was not designed to prove causal-
ity between HZ and varicella vaccination [34, 35]. Fac-
tors that may have influenced an increase in HZ
incidence include increasing elderly population [36],
increased oral corticosteroid use [37], and, chronic co-
morbid conditions [38, 39]. Therefore this paper focuses
solely on the impact of influential factors on varicella.
Limitations of this study relate to the underlying
model assumptions for which a lack of evidence exists;
such as duration of immunity after two doses or waning
of natural immunity and two-dose vaccine efficacy for
full or partial or non-responders. In order to focus on
the influential factors of interest for this study, the same
simplified catch-up programme was implemented in all
dosing scenarios. Although a conservative catch-up
coverage of 20 % was used, the catch-up duration was
11 years based on the needs for the long-interval dosing
schedule (i.e., after 11 years the first infants vaccinated
would receive their second routine dose), and may there-
fore have artificially improved the outcomes in this
dosing scenario. Despite this, the long-interval dosing
scenarios had the worst predicted outcomes (among
two-dose schedules). Therefore, the effect of using a
simplified catch-up programme on results was expected
to be minor in long-interval dosing scenarios. In this
study, despite the low coverage of the catch-up
programme, it was found to be beneficial in reducing
the peak of cases predicted to occur around ten years
after implementing RVV among older children in both
one-dose and two-dose strategies. This finding has also
been observed in other modelling studies of RVV [3]. All
Italian regions may introduce a catch-up programme for
susceptible adolescents, since this was offered by the
National Vaccination Plan in 2012–2014, although
coverage of the catch-up programme may vary across
the different regions [6, 20].
The impact of different vaccination scenarios on
payers’ budget and cost-effectiveness ratios have not
been assessed in the current study. Scenarios with higher
coverage, more doses and catch - up will have increased
vaccination programme cost, however, this increase
needs to be balanced against expected larger cost savings
due to better disease prevention (e.g., reductions in re-
source utilisation and lost productivity). Published eco-
nomic evaluations have found that introducing both
one- and two-dose RVV strategies are cost-effective from
payer perspectives and even cost-saving from societal
perspectives [40].
Conclusion
The current study may provide insights for policy
makers on how to optimally reduce the burden of vari-
cella in their country. Coverage of varicella vaccination
is a critical factor in significantly reducing the number
of varicella cases, whether for a one-dose strategy or a
two-dose strategy. The combination of high coverage
with dosing intervals of five years or less was more ef-
fective at preventing varicella than longer dosing inter-
vals. A high coverage can compensate to some extent for
decreases in cases prevented due to long intervals be-
tween doses. Similarly, at a lower coverage, varicella pre-
vention was improved with short interval dosing
schedules. Coverage had a greater impact on vaccination
outcomes than the efficacy of the first dose or the dosing
interval. The catch-up programme substantially reduced
the peak in cases after ten years of introducing child-
hood RVV, even with a modest vaccine coverage in
adolescents.
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